Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Evotec SENASDAQ: EVO
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was -€38.36M, compared with -€20.13M a year earlier.
Context
- Accumulated OCI amounted to 2.3% of total assets at the end of Q1 FY2026, up 1.4 pp from a year earlier.
- Accumulated OCI grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -90.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
EUR · from the balance sheet
- Latest · FY2025
- (45.09M) EUR
- Year-over-year change
- -513.7%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.09M) | -513.7% |
| FY2024 | 2024-12-31 | (7.35M) | +76.0% |
| FY2023 | 2023-12-31 | (30.64M) | +18.1% |
| FY2022 | 2022-12-31 | (37.4M) | -195.9% |
| FY2021 | 2021-12-31 | (12.64M) | — |
Accumulated OCI vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -90.5% is the 7th highest of 10, against a peer median of +4.9%.
- Accumulated OCI amounts to 2.3% of total assets for EVO, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €56.99M EUR | +20.5% | +35.7% | 19.3% | |
| Mar 2026 | $16.6M USD | +7.8% | -17.0% | 1.2% | |
| Mar 2026 | $3.46M USD | +155.7% | — | 0.3% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | -$131K USD | -265.8% | — | 0.0% | |
| Mar 2026 | -$4.9M USD | -16.5% | — | 0.6% | |
| Sep 2026 | -$5.38M USD | -780.4% | — | 0.5% | |
| Mar 2026 | -$35.42M USD | +4.9% | — | 1.3% | |
| Mar 2026 | -€38.36M EUR | -90.5% | — | 2.3% | |
| Feb 2026 | -$44.2M USD | +42.2% | — | 2.1% | |
| Sep 2026 | -$77.4M USD | -248.4% | — | 4.5% | |
| Peer median (excluding EVO) | — | +4.9% | +9.4% | 0.9% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 699.33M | 400.7M | 510.91M | 306.39M | 418.34M |
| Short-term Investments | 159.17M | 306.61M | 93.2M | 90.41M | 57.85M |
| Net Receivables | 176.75M | 275.77M | 221.9M | 218.38M | 213.42M |
| Inventory | 25.79M | 29.83M | 30.89M | 31.12M | 29.3M |
| Other Current Assets | 20.69M | 43.82M | 27.87M | 13.42M | 24.75M |
| Total Current Assets | 1.1B | 1.07B | 903.16M | 681.96M | 762.62M |
| Property, Plant & Equipment (Net) | 484.6M | 650.2M | 806.56M | 823.94M | 554.39M |
| Goodwill | 257.57M | 274.82M | 275.64M | 282.85M | 272.25M |
| Intangible Assets | 30.85M | 23.82M | 15.45M | 26.44M | 31.56M |
| Long-term Investments | 287.01M | 150.33M | 142.09M | 42.15M | 52.61M |
| Tax Assets | 17.36M | 10.33M | 14.33M | 17.33M | 67.73M |
| Other Non-current Assets | 56.84M | 74.08M | 95.23M | 37.82M | 36.84M |
| Total Non-current Assets | 1.13B | 1.18B | 1.35B | 1.23B | 1.02B |
| Total Assets | 2.24B | 2.26B | 2.25B | 1.91B | 1.78B |
| Account Payables | 72.6M | 97.28M | 134.32M | 85.79M | 64.74M |
| Short-term Debt | 36.14M | 1.56M | 149.1M | 50.8M | 103.64M |
| Tax Payables | 10.6M | 10.84M | 8.36M | 13.97M | 0 |
| Deferred Revenue | 126.78M | 136.67M | 107.86M | 109.82M | 108.02M |
| Other Current Liabilities | 63.93M | 76.54M | 45.83M | 84.21M | 41.18M |
| Total Current Liabilities | 324.52M | 337.71M | 464.57M | 344.59M | 367.92M |
| Long-term Debt | 326.34M | 328.3M | 477.11M | 392.74M | 194.82M |
| Deferred Tax Liabilities | 17.69M | 18.52M | 18.14M | 14.52M | 79.51M |
| Deferred Revenue (Non-current) | 34.48M | 206.14M | 155.29M | 187.24M | 153.61M |
| Other Non-current Liabilities | 18.49M | 17.4M | (152.57M) | 20.9M | 19.74M |
| Total Non-current Liabilities | 532.96M | 732.36M | 667.99M | 615.39M | 596.72M |
| Total Liabilities | 857.48M | 1.07B | 1.13B | 959.98M | 964.64M |
| Common Stock | 176.61M | 176.95M | 177.19M | 177.55M | 177.7M |
| Retained Earnings | (216.42M) | (392.38M) | (476.29M) | (672.37M) | (775.56M) |
| Accumulated OCI | (12.64M) | (37.4M) | (30.64M) | (7.35M) | (45.09M) |
| Other Stockholders Equity | 0 | 0 | 1K | 1K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.38B | 1.19B | 1.12B | 952.53M | 813.36M |
| Total Debt | 512.92M | 506.67M | 815.35M | 443.54M | 447.5M |
| Net Debt | (186.41M) | 105.98M | 304.44M | 137.15M | 29.16M |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.